novo nordisk products

News

Novo Nordisk to develop new obesity pills

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

UPI on MSN · 23h

Novo Nordisk, U.S. biotech company team up to create obesity pills

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Benzinga · 3d

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.

Novo Nordisk ousts CEO

Reuters on MSN · 23h

From insulin to Ozempic, history of Novo Nordisk's CEOs

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli Lilly .

pharmaphorum · 1d

Novo Nordisk's dropping share price spells the end for CEO

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation and former Novo Nordisk CEO, Lars Rebien Sørensen, is joining the pharma company's board, initially as an observer.

CBS News on MSN · 1d

Novo Nordisk CEO, who led company into weight-loss drugs, to step down

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual agreement."

Zacks Investment Research on MSN1d

Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Novo Nordisk CEO steps down in surprise move as 'market challenges' weigh on obesity drugmaker

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

pharmaphorum4d

Novo Nordisk builds case for Norditropin successor

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

PharmExec23h

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

GlobalData on MSN3d

Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk ousts boss as Ozempic maker battles slump

Novo Nordisk has announced that chief executive Lars Fruergaard Jørgensen will step down just days after the pioneering maker of obesity drugs cut its profit forecast. The Danish group said on Friday ...

Novo Nordisk, Charter & Cox, Take Two: Trending Tickers

CEO Lars Fruergaard Jørgensen is set to step down. Charter (CHTR) and Cox Communications announce a merger in a $34.5 billion ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results